These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8669666)

  • 1. Complex pharmacology of malignant hyperthermia.
    Pessah IN; Lynch C; Gronert GA
    Anesthesiology; 1996 Jun; 84(6):1275-9. PubMed ID: 8669666
    [No Abstract]   [Full Text] [Related]  

  • 2. [Receptors, genetics and malignant hyperpyrexia].
    Shapira Y; Gurman GM
    Harefuah; 1997 Jun; 132(12):849-50. PubMed ID: 9264191
    [No Abstract]   [Full Text] [Related]  

  • 3. Dantrolene sodium can increase or attenuate activity of skeletal muscle ryanodine receptor calcium release channel. Clinical implications.
    Nelson TE; Lin M; Zapata-Sudo G; Sudo RT
    Anesthesiology; 1996 Jun; 84(6):1368-79. PubMed ID: 8669678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ca2+ channels and excitation-contraction coupling.
    Ashcroft FM
    Curr Opin Cell Biol; 1991 Aug; 3(4):671-5. PubMed ID: 1663374
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of propofol on Ca2+ regulation by malignant hyperthermia-susceptible muscle membranes.
    Fruen BR; Mickelson JR; Roghair TJ; Litterer LA; Louis CF
    Anesthesiology; 1995 May; 82(5):1274-82. PubMed ID: 7741303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The sarcoplasmic reticulum Ca2+ channel/ryanodine receptor: modulation by endogenous effectors, drugs and disease states.
    Zucchi R; Ronca-Testoni S
    Pharmacol Rev; 1997 Mar; 49(1):1-51. PubMed ID: 9085308
    [No Abstract]   [Full Text] [Related]  

  • 7. Dantrolene : From Malignant Hyperthermia to Alzheimer's Disease.
    Shi Y; Wang Y; Wei H
    CNS Neurol Disord Drug Targets; 2019; 18(9):668-676. PubMed ID: 29921212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agonist-activated, ryanodine-sensitive, IP3-insensitive Ca2+ release channels in longitudinal muscle of intestine.
    Kuemmerle JF; Murthy KS; Makhlouf GM
    Am J Physiol; 1994 May; 266(5 Pt 1):C1421-31. PubMed ID: 7515567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drug-induced malignant hyperthermia].
    Ichihara Y; Kikuchi H
    Nihon Rinsho; 2007 Oct; 65 Suppl 8():326-30. PubMed ID: 18074557
    [No Abstract]   [Full Text] [Related]  

  • 10. Malignant hyperthermia: a pharmacogenetic disorder.
    Stratman RC; Flynn JD; Hatton KW
    Orthopedics; 2009 Nov; 32(11):835. PubMed ID: 19902883
    [No Abstract]   [Full Text] [Related]  

  • 11. Dantrolene does not block calcium pulse-induced calcium release from a putative calcium channel in sarcoplasmic reticulum from malignant hyperthermia and normal pig muscle.
    Nelson TE
    FEBS Lett; 1984 Feb; 167(1):123-30. PubMed ID: 6321231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant Hyperthermia: From the OR to the Sidelines.
    Nelson TE
    Curr Sports Med Rep; 2018 Aug; 17(8):254-255. PubMed ID: 30095544
    [No Abstract]   [Full Text] [Related]  

  • 13. Dantrolene and azumolene inhibit [3H]PN200-110 binding to porcine skeletal muscle dihydropyridine receptors.
    el-Hayek R; Parness J; Valdivia HH; Coronado R; Hogan K
    Biochem Biophys Res Commun; 1992 Sep; 187(2):894-900. PubMed ID: 1326958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced excitation-coupled calcium entry in myotubes expressing malignant hyperthermia mutation R163C is attenuated by dantrolene.
    Cherednichenko G; Ward CW; Feng W; Cabrales E; Michaelson L; Samso M; López JR; Allen PD; Pessah IN
    Mol Pharmacol; 2008 Apr; 73(4):1203-12. PubMed ID: 18171728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Porcine malignant hyperthermia: effect of dantrolene sodium on in-vitro halothane-induced contraction of susceptible muscle.
    Anderson IL; Jones EW
    Anesthesiology; 1976 Jan; 44(1):57-61. PubMed ID: 1244776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of ryanodine receptors.
    Ogawa Y
    Crit Rev Biochem Mol Biol; 1994; 29(4):229-74. PubMed ID: 8001396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Malignant hyperthermia].
    Ording H; Bendixen D
    Nord Med; 1992; 107(1):12-4. PubMed ID: 1310356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long term oral Dantrolene Improved Muscular Symptoms in a Malignant Hyperthermia Susceptible Individual.
    Butala BN; Kang A; Guron J; Brandom BW
    J Neuromuscul Dis; 2016 Mar; 3(1):115-119. PubMed ID: 27854207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignant hyperthermia: an inherited disorder of skeletal muscle Ca+ regulation.
    Louis CF; Balog EM; Fruen BR
    Biosci Rep; 2001 Apr; 21(2):155-68. PubMed ID: 11725864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical protocol for the management of malignant hyperthermia.
    Kollmann-Camaiora A; Alsina E; Domínguez A; Del Blanco B; Yepes MJ; Guerrero JL; García A
    Rev Esp Anestesiol Reanim; 2017 Jan; 64(1):32-40. PubMed ID: 27633384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.